Toby Maher, MD, PhD, professor of clinical medicine, Keck Medicine of USC, discusses the impact of changes in lung function in patients with idiopathic pulmonary fibrosis (IPF). How does the rate of ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Oral nerandomilast doses of 9 mg and 18 mg were ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Two differing nerandomilast doses were assessed against ...
SAN FRANCISCO — The investigational oral agent nerandomilast was superior to placebo at slowing the decline in forced vital capacity (FVC) among patients with progressive pulmonary fibrosis (PF), ...
Parametric survival modeling from FIBRONEER-IPF projected median survival of 3.7 years on placebo versus 5.8 and 9.1 years with nerandomilast 9 mg and 18 mg monotherapy. Background nintedanib ...
Among individuals in the general population with at least 10 pack-years of cigarette smoking who undergo spirometry, 12% have a post-bronchodilator FEV 1 % predicted below 80% with a FEV 1 /FVC ratio ...
There's a certain kind of pop music that hides its hooks under abstract influences and aggressive noise. London newcomer Florence Van Camerijk, who performs as FVC, is no stranger to this phenomenon.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results